ANDBANK
wealth management

YSIOS CAPITAL

Telescope Biotech Fund

Invest in the future of medicine

US PUBLIC EQUITIES FUND

SPECIALIZED IN INNOVATIVE BIOTECH

GROWTH-DRIVEN PORTFOLIO WITH 2-4 YEAR HORIZON

Index

01. Investment brochure 3
- 01.1 Executive summary 4

02. The Biotech Sector - Disruptive innovation and growth with high impact for society 5
- 02.1 A golden era in biomedical innovation 6
- 02.2 The pharmaceutical industry relies on external R&D 7
- 02.3 US-listed companies capture worldwide biotech growth 8
- 02.4 Pharma will continue acquiring biotech companies 9
- 02.5 Biotech is recovering from an interest rate-driven bear market 10
- 02.6 Biotech is a stock picker's market 11

03. A gateway to the leading biotech companies 12
- 03.1 Investment advisor: Ysios Capital 13
- 03.2 Investment philosophy 15
- 03.3 Portfolio composition 16
- 03.4 Biotech is a stock picker's market 17
- 03.5 Analysis: The Voyager engine 18
- 03.6 Areas of investment 19
- 03.7 Investment opportunities 20
- 03.8 Case study: Antibody-drug conjugates (ADCs) 21

04. Information for Investors 23
- 04.1 Communication 24
- 04.2 Investment summary 25



YSIOS CAPITAL
TBF

01.

Investment brochure

01.1 Executive summary



Structure

Investment fund in publicly traded **biotech and pharma companies**

Focus on **US markets: Nasdaq and NYSE**

Vehicle: *Fondo de Inversión Libre (FIL)*

Strategy

Portfolio of 15-20 companies with a **mid-term horizon (2-4 years)**

Investment in medicines and teams. **Driven by fundamentals**

Specialized approach guided by **Ysios Voyager:** a proprietary research engine

Opportunity

Biomedical innovation is going through a golden era

The biotech sector is fueled by **pharma M&A**

Reset of valuations in the sector provides attractive entry point

Managed by
ANDBANK
wealth management

Invest with the experience
of a leading fund manager and a biotech VC firm

Investment advisor
YSIOS CAPITAL

The Biotech Sector

02.

Disruptive innovation and growth with high impact for society

02.1 A golden era in biomedical innovation

Compounding returns for patients

In obesity
GLP-1 agonists

novo nordisk®

Lilly

$47B In combined 2024 sales

Against cancer
Antibody-drug conjugates



Seagen®

$43B Acquisition by Pfizer | 2023

immunogen

$10B Acquisition by Abbvie | 2023

Facing a pandemic
mRNA vaccines

moderna

Pfizer

BIONTECH

$56B Peak mRNA sales in 2022

02.2 The pharmaceutical industry relies on external R&D

Most new medicines are developed by small companies financed by capital markets

Pharma products largely come from acquisitions



Source of FDA-approved drugs filed by top20 biopharma companies 2015-2021.
Source: Nature Reviews Drug Discovery, 2023



of blockbuster drugs*
are acquired, licensed or co-developed

*Drugs with >$1B annual sales (2022). Source: Globaldata

Biotech M&A continues along a growth trajectory

2023 was a record year for development-stage biotech



M&A values for <$10B public biotech companies. The acquisition premium is calculated based on deal price vs the average price in the 20 days before the deal was announced. Source: Semper Maior, Rapport Bio, 2024

- Big pharma companies have strong sales footprints that **depend on external innovation** to fill their commercial pipelines
- Acquirers are willing to pay **substantial premiums** for clinically validated assets

02.3 US-listed companies capture worldwide biotech growth

The medicines market is global, but the center of innovation is in US listings

Global medicine market size and growth, 2015-2028



Source: EvaluatePharma

- Biotech and pharma are growing markets due to **population increase and aging**
- Economic growth in **emerging regions** is driving increased drug spending and making the medicines market global
- Growth in the medicines market is driven by branded products, developed through investment in innovation

Companies listed in **Nasdaq** and **NYSE** receive the predominant share of **biotech and pharma M&A**

Destination of M&A proceeds, 2018-2023

All deals

Includes upfront payments in all biopharma deals >$50M in value in the indicated period

93% **US-listed** companies



6% private companies

0.3% listed ex-US

Excluding megamergers

Includes upfront payments in all biopharma deals >$50M and <$10B in value in the indicated period

82% **US-listed** companies



17% private companies

0.8% listed ex-US

M&A proceeds sorted by type of company that is acquired. Source: Ysios Voyager

02.4 Pharma will continue acquiring biotech companies

Biotech M&A targets carry acquisition premium

Revenue loss due to patent expiry is the main driver for M&A

Sales at risk due to US loss of exclusivity



Sales at risk: a drug's annual revenue in the year before loss of exclusivity; shown are US sales and US patent expiries within the biopharma industry.
Source: Evaluate Pharma

130
Drugs losing patent exclusivity by 2030

46%
Estimated revenue loss over the next decade for Top10 pharma

>$300B
Sales at risk by 2031

Top drugs facing generic challenge in the next five years

	Key patent expiration	2023 sales
KEYTRUDA	2028	$25B
Eliquis	2027	$12.2B
OPDIVO	2028	$10B
EYLEA	2027	$9.7B
IBRANCE	2028	$4.7B

Pharma is sitting on large amounts of cash



>$600B Available for M&A

M&A FIREPOWER ($B)

Cash plus amount of debt a company can take on given current EBITDA to arrive at a ratio of net debt to EBITDA of three times. Data as of Q4 2024.
Source: Company filings and Ysios Voyager

02.5 Biotech is recovering from an interest rate-driven bear market

Reset of valuations provides unique entry point

XBI: SPDR S&P Biotech

ETF that tracks US-listed biotech companies



Fastest interest rate increase by the Federal Reserve in four decades induced steep decline in innovation-driven growth sectors

Major growth industries all faced downward pressures in 2021-2023

Index	Sector	Peak to trough
XBI	Biotech	↓ 64%
SOCL	Social media	↓ 69%
IPO	Newly listed	↓ 69%
QCLN	Green energy	↓ 63%
MSW	Software	↓ 45%
XLK	Internet	↓ 35%

02.6 Biotech is a stock picker's market

High upside sector that requires active portfolio management

Biotech returns are driven by outlier successes

XBI individual components, Jan 2023-Dec 2024 annualized returns



- Biotech stocks exhibit **a wide range of returns**
- **Active management and specialization** are crucial to build performance
- Short-term action will be influenced by macro and market volatility, but over time success is determined by **individual selection**

Annualized returns over the indicated period for each of the stocks that are part of the XBI index. The blue box indicates the interquartile range with the median value inside. Whiskers extend to the highest and lowest typical returns, while dots represent outliers.
Source: Ysios Telescope

Positive data gets rewarded, despite market conditions

Price per share. 2019-2023 range



YSIOS CAPITAL
TBF

Telescope
Biotech Fund

03. A gateway to the leading biotech companies

03.1a Investment advisor: Ysios Capital

Spain's largest biotech investor

YSIOS CAPITAL

Founded in **2008**

Three biotech venture funds raised

YBFI (2008)
€65M

YBFII (2015)
€126M

YBFIII (2020)
€216M

Nineteen products taken to market

Imlygic
for metastatic melanoma

QIAstat
for rapid diagnostic of respiratory disease

Proven investment track record

Nasdaq
6 IPOs

M&A
8 portfolio companies acquired

03.1b Investment advisor: Ysios Capital

Spain's largest biotech investor

Advisory team

Jordi Xiol, PhD
Partner and Lead Advisor

EMBL · HARVARD UNIVERSITY · VIDA ventures

Almudena Méndez, PhD
Analyst

CNB Centro Nacional de Biotecnología · Politécnica · Universidad Politécnica de Madrid

Sriram Balusu, PhD
Analyst

VIB science meets life · Ghent University

Supported by team of 15+ biotech investors and industry specialists

GLYCART biotechnology · McKinsey & Company · Genentech · SANIFIT · AMGEN · almirall · andera PARTNERS · IMMUNE DESIGN · TalDe · Gimv · CUATRECASAS · pwc · Deusto · ALANTRA

03.2 Investment philosophy

Sweet spot investing

Investment in listed biotech and pharma: **long-only** + options

Focused research and expertise around selected therapeutic areas and modalities

"The stock market is a non-called strike game. You don't have to swing at everything – you can wait for your pitch"

Warren Buffett

Guiding principles

Knowledge

- Investment decisions are knowledge-based
- The more knowledge, the better decisions

Patients

- The most valuable drugs are those that help patients the most
- Returns and impact go hand in hand

Market

- Fit between drug profile and market positioning
- Direct contact with pharma to understand commercial prospects

Focus

- Highly specialized within area of expertise
- Assessments driven by data, not sentiment

We will only swing in our sweet spot

If an opportunity is not **within our circle of competence,** we will not invest

03.3 Portfolio composition

Investment thesis based on fundamentals

Invested capital

20-25% 1-2 Large CAP	>$10B market cap, commercial-stage Establish thesis to identify sector leader Moderate to low risk
40-50% 7-10 Clinically validated companies	>$500M market cap Focus on M&A candidates Moderate risk
20-25% 7-10 Early-stage companies	>$50M market cap No clinical proof-of-concept High-risk/high-reward opportunities
<10% Options and cash	Options: buy calls and puts Hedge Dry powder for market overreactions

"If you want to have a better performance than the crowd, you must do things differently from the crowd"

John Templeton

Six months to construct portfolio

Unallocated capital partially invested in XBI to gain sector exposure

Mid and long-term vision

Success is a function of maturing clinical data. Investment thesis needs 2-4 years

Let the winners realize their potential

As a FIL, the Fund can hold more than 10% in a single company

Distinctive strategy diverging from benchmarks

The Fund will not replicate any index and will not be biased by momentary trends

03.4 Investment Strategy

"What really counts in the growth stock is the future"

Philip Fisher

Growth-Driven / Main focus of the fund

Fundamentally undervalued companies

- Identify undervalued element: data, market, label expansion, pharma interest, competitive positioning
- Success stories grow progressively over time, not just on event days

Price per share (2019-2023 range)



+958%
Immunology
CLDX

+285%
Rare disease
ARGX

+419%
Metabolic disease
NVO

★ Key data events

Event-Driven / Source of Alpha, but limited exposure

Clinical trial readout / Regulatory decision

- Timed investment on anticipated milestones with binary outcome
- Contrarian view to priced-in expectations
- Opportunistic buys to take advantage of market overreactions upon data release

Valuation method

Research-based approach to DCF



03.5 Analysis: The Voyager engine

Ysios Capital's proprietary research database to guide investment decisions

The Ysios Capital team generates a comprehensive map of drug development landscape. It is the main resource used to evaluate investment opportunities

Indication-Based

- **Pathophysiology:** causes and stages, unmet medical need
- **Epidemiology:** prevalence, incidence, patient population
- **Market:** pricing potential, payor and reimbursement
- **Treatment paradigm:** lines of therapy, real-world drug usage
- **Regulatory:** endpoints, trial design, requirements for approval
- **Biopharma landscape:** pipeline of emerging drugs and deals

Two research verticals

Company-Based

- **Scientific rationale:** target, modality, preclinical data
- **Development path:** clinical data, regulatory, CMC
- **Management team:** track record, execution, credibility
- **Investor base:** strength, conviction, expertise
- **Financial and IP:** cap structure, cash runway, IP estate
- **Valuation/exit:** revenue modelling, scenarios, buyer universe

YSIOS CAPITAL

3,000+
Companies evaluated

+500
Key opinion leaders engaged

19
Pharma companies coinvested with

22
Biotech financings led and co-led

03.6 Areas of investment

Specialization is an edge

Focus on core pharma markets

Select therapeutic areas for investment



Oncology



Immunology



Rare disease



Metabolic disease

We are looking for good assets in **bread and butter pharma areas** that we understand

Maximize overlap between team expertise and pharma M&A footprint

M&A deals of public biotech companies - Upfront payment >$1B, 2022-2023 range

Company	Acquirer	Upfront ($B)	Therapeutic Area
Seagen	Pfizer	43	**Oncology**
Horizon Therapeutics	Amgen	28.3	**Rare disease**
Karuna Therapeutics	Bristol-Myers Squibb	14	Neurology
Biohaven Pharmaceutical	Pfizer	12.2	Neurology
Prometheus Biosciences	Merck	10.8	**Immunology**
ImmunoGen	AbbVie	10.1	**Oncology**
Cerevel Therapeutics	AbbVie	8.7	Neurology
Reata Pharmaceuticals	Biogen	7.3	**Rare disease**
IVERIC bio	Astellas Pharma	5.9	**Immunology**
Global Blood Therapeutics	Pfizer	5.4	**Rare disease**
Mirati Therapeutics	Bristol-Myers Squibb	4.8	**Oncology**
RayzeBio	Bristol-Myers Squibb	4.1	**Oncology**
Turning Point Therapeutics	Bristol-Myers Squibb	4.1	**Oncology**
ChemoCentryx	Amgen	3.7	**Immunology**
Chinook Therapeutics	Novartis	3.2	**Immunology**
Provention Bio	Sanofi	2.9	**Metabolic disease**
DICE Therapeutics	Eli Lilly	2.4	**Immunology**
Affinivax	GSK	2.1	Infectious disease
Ambrx Biopharma	Johnson & Johnson	2	**Oncology**
BELLUS Health	GSK	2	Respiratory
Sierra Oncology	GSK	1.9	**Oncology**
Zogenix	UCB	1.9	**Rare disease**
Myovant Sciences	Sumitovant Biopharma	1.7	**Oncology**
POINT Biopharma Global	Eli Lilly	1.4	**Oncology**
Imago BioSciences	Merck	1.4	**Oncology**
CinCor Pharma	AstraZeneca	1.3	Cardiovascular
Amryt Pharma	Chiesi Farmaceutici	1.3	**Rare disease**
Gracell Biotechnologies	AstraZeneca	1.2	**Oncology**
Icosavax	AstraZeneca	1.1	Infectious disease
Forma Therapeutics	Novo Nordisk	1.1	**Rare disease**
Inversago Pharma	Novo Nordisk	1.1	**Metabolic disease**
VectivBio	Ironwood Pharmaceuticals	1	**Rare disease**

Large pharma M&A deals fall within selected therapeutic areas

03.7 Investment opportunities

Exhaustive tracking and analysis

Deal flow pipeline

Analysis is entirely **data-driven**, but investment decision incorporates **human factor**: direct relationship with management teams, investor base, and potential acquirers

All US-listed drug development companies + EU-listed pharma companies



03.8a Case study: Antibody-drug conjugates (ADCs)

Core area of Ysios expertise offering high-return opportunities

Technology

ADCs

Targeted chemotherapy

++ Increased specificity
++ Better tolerability

Top approved drugs

ENHERTU
fam-trastuzumab deruxtecan-nxki

$2.6B
Breast cancer
(2023 sales)

TRODELVY

$1.1B
Breast cancer
(2023 sales)

ADCETRIS
brentuximab vedotin

$900M
Hodgkin lymphoma
(2023 sales)

PADCEV
enfortumab vedotin-ejfv

$600M
Bladder cancer
(2023 sales)

Recent M&A (US-listed companies)

	Acquirer	Price	M&A Premium*	1-year return**	2-year return**
AMBRX	J&J (2024)	$2B	105%	1025%	275%
Seagen	Pfizer (2023)	$43B	33%	46%	35%
immunogen	Abbvie (2023)	$10B	95%	466%	376%
Immunomedics	Gilead (2020)	$21B	108%	404%	288%

* Price increase on the day of M&A announcement
** Calculated as returns in the period prior to M&A announcement

>$12B in **additional licensing deals** (2019-2024)

33 listed **biopharma companies** with active ADC programs

03.8b Case study: Antibody-drug conjugates (ADCs)

Core area of Ysios expertise offering high-return opportunities

Ysios know-how

Early-stage ADC investments

adcendo

$62M Series A in 2021

$135M Series B in 2024

TAG WORKS

$65M Series A in 2023

Key insights

YSIOS CAPITAL

Working with leading stakeholders

Michael Pehl	*Adcendo CEO/Former Immunomedics CEO*
Carmel Lynch	*Adcendo CDO/Former Seagen Sr Director*
Dennis Benjamin	*Adcendo SAB/Former Seagen VP*
John Lambert	*Adcendo SAB/Immunogen Founder and former CSO*
Jay Feingold	*Tagworks CMO/Former ADC Therapeutics CMO*

Continued discussion with dedicated pharma BD teams and TA heads

Pfizer · Johnson & Johnson · MERCK · AstraZeneca · Boehringer Ingelheim · abbvie · Roche

Map of technological and asset landscape in place

+100

ADC assets evaluated

KOLs

Select group of market-moving opinion leaders engaged as consultants

YSIOS CAPITAL
TBF

04.

Information for Investors

04.1 Communication

Investors can closely follow performance and investment strategy

Monthly

Publication of **Net Asset value (NAV)**

Letter to Investors:
comment on markets and portfolio

Quarterly

Extended Investor Report with key facts, figures, and outlook

Informe Público Periódico (IPP, biannual)

Annual

Annual accounts

Investor webinar

ANDBANK Private Bankers

Resources

Web and app interface
Track positions and perform operations

Media

Monthly podcast on most relevant biotech news

Spotify Apple

04.2 Investment summary

Key Features

Spain-based vehicle for **US-listed** biotech investments

Management and advisory firms have **top-tier investment record**

Biotech is a blooming sector providing an opportunity for high growth

Mid-term target return above XBI

Terms

1.2% management fee. **0.9%** for tickets >€1M

12% success fee with high-water mark provision

1-year initial commitment, then quarterly liquidity windows with 30-day notice

Minimum ticket: **€100k**

The opportunity is now

CONTACTO: 900 255 256 / 91 000 59 37 negocio.esis@andbank.es

Disclaimer

El contenido de este documento se proporciona únicamente con fines informativos y no constituye una oferta de venta ni una solicitud de oferta para comprar ningún producto de inversión. El fondo está sujeto a requisitos legales y regulatorias aplicables en España, y cualquier potencial inversor debe revisar los términos del fondo en los documentos formales de oferta antes de invertir. Las inversiones en Fondos de Inversión Libre implican un alto grado de riesgo, incluyendo la posible pérdida del capital invertido, y pueden no ser adecuadas para todos los inversores. El rendimiento pasado no es indicativo de resultados futuros.

The content herein is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any investment product. The fund is subject to legal and regulatory requirements applicable in Spain, and any potential investor must review the fund's terms in the formal offering documents before making any investment. Investing in Fondos de Inversión Libre involves a high degree of risk, including the potential loss of the invested capital, and may not be suitable for all investors. Past performance is not indicative of future results.